The first anniversary of new drug "Kemena" of Beida Pharmaceutical Co., Ltd. being included in Zhejiang medical insurance

Five experts from Beida's national "thousand talents plan" gathered at Kemena's achievement conference to talk about the "pacesetter" in the research and development of domestic anti-cancer drugs in Hangzhou I believe many people will think of Beida pharmaceutical This high-tech enterprise, founded by the returnees' team, focuses on the research and development of innovative drugs with independent intellectual property rights Since its establishment, it has been committed to the research and development and production of national first-class new drugs with independent intellectual property rights, focusing on the theme of "anti-cancer" Kemena, the only small molecule targeted anti-cancer drug with independent intellectual property rights in China, is known as the "two bombs and one star" in the pharmaceutical industry, which is the "representative work" of Beida pharmaceutical industry By virtue of Kemena, which has been nurtured for ten years, Beida pharmaceutical has won the first place in the growth group of China Innovation and entrepreneurship competition and Zhejiang competition last year At the moment when Beida pharmaceutical won the award (information chart) meeting, the person in charge of the Department of human resources and social security of Zhejiang Province introduced the experience of taking the lead in bringing exetinib hydrochloride (Kemena) into medical insurance in China In particular, innovative measures such as medical insurance negotiation, opening pharmacies and canceling gene monitoring have been adopted to enable Zhejiang patients to enjoy medical insurance as long as they have received chemotherapy and benefited from the use of exetane In this regard, experts at the meeting think that this initiative has brought a good reference model to the whole country If Zhejiang experience can be successfully extended to Beijing, Shanghai, Guangzhou and other important cities and even the whole country, new drugs can be better used in clinical practice, truly benefiting the people and benefiting the people, and more ordinary people can get the international leading medical security Ding liming, chairman of Beida pharmaceutical, said that at present, "Kemena" has been included in the medical insurance catalogue of nine cities in Zhejiang Province and Qingdao, Shandong Province and other places In these cities, patients only need to pay more than 10000 yuan at their own expense to take new drugs for a long time, while the monthly cost of imported drugs is 16500-19800 yuan Compared with the imported drugs, the main efficacy index of "Kemena" is 34% higher, the main adverse reactions are significantly lower than the control group, and the safety is better "Kemena has definite efficacy and safety for Chinese patients It is a clinical study completed among Chinese patients, and its research results fully adapt to all Chinese patients It is tailored for Chinese patients." Ding Liming said that if patients take "Kemena" for six months, they will be free of charge in the future.